ReviewIndian journal of clinical biochemistry : IJCB2021
Interleukin-6 Perpetrator of the COVID-19 Cytokine Storm.
Review in Indian journal of clinical biochemistry : IJCB, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 84 citations in OpenAlex.
- Longitudinal transcriptional analysis of peripheral blood leukocytes in COVID-19 convalescent donors.Journal of translational medicine · 2022Trial
- The Association Between Peak IL-6 Levels, In-Hospital Mortality, and Selected Risk Factors in Patients Hospitalized for COVID-19 at the Temporary Hospital in Gdansk-A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Exploring the timeline and network interplay of immune mediators in COVID-19 patients according to disease outcome.Frontiers in immunology · 2026Observational
- Serum IL-6 and IL-18 responses in COVID-19 in children: the role of vitamin D status in a cohort from Azerbaijan.Frontiers in pediatrics · 2026Article
- Hemodynamic and Clinical Predictors of Thrombolysis in Post-COVID Venous Thromboembolism: A Retrospective Cohort Study.Biomedicines · 2025Article
- Review
- Review
- Chronic Obstructive Pulmonary Disease and COVID-19: The Impact of Hematological Biomarkers on Disease Severity and Outcomes.Journal of clinical medicine · 2025Review
- Investigating T Cell Immune Dynamics and IL-6's Duality in a Microfluidic Lung Tumor Model.ACS applied materials & interfaces · 2025Article
- Omega-3 Polyunsaturated Fatty Acids in Chronic Obstructive Pulmonary Disease Patients with COVID-19: A Review.Current nutrition reports · 2025Review
- IL 6 Cascade in Post COVID Cardiovascular Complications: A Review of Endothelial Injury and Clotting Pathways.Cardiovascular & hematological disorders drug targets · 2025Review
- Exploring Micronutrient Dynamics in COVID-19 Severity and Mortality: Unraveling the Roles of Vitamin D, Calcium, Phosphorus, Magnesium and ALP.Indian journal of clinical biochemistry : IJCB · 2024Article
- Immulina® mitigates the development of illness when administered during the prodromal period of influenza viral infection in mice (Part 2).Phytomedicine : international journal of phytotherapy and phytopharmacology · 2024Article
- Impaired instructive and protective barrier functions of the endothelial cell glycocalyx pericellular matrix is impacted in COVID-19 disease.Journal of cellular and molecular medicine · 2024Review
- Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.Heliyon · 2024Article
- Ketamine-based Sedation Use in Mechanically Ventilated Critically Ill Patients with COVID-19: A Multicenter Cohort Study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination.Blood neoplasia · 2024Article
- Evaluation of clinically relevant serum proteins as biomarkers for monitoring COVID-19 severity, and end-organ damage among hospitalized unvaccinated patients.BMC infectious diseases · 2024Article
- The single nucleotide polymorphism rs4986790 (c.896A>G) in the geneFrontiers in immunology · 2024Article
- Hyper-induction of IL-6 after TLR1/2 stimulation in calves with bovine respiratory disease.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 has emerged as a global pandemic. It is mainly manifested as pneumonia which may deteriorate into severe respiratory failure. The major hallmark of the disease is the systemic inflammatory immune response characterized by Cytokine Storm (CS). CS is marked by elevated levels of inflammatory cytokines, mainly interleukin-6 (IL-6), IL-8, IL-10, tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ). Of these, IL-6 is found to be significantly associated with higher mortality. IL-6 is also a robust marker for predicting disease prognosis and deterioration of clinical profile. In this review, the pivotal role played by IL-6 in the immuno-pathology of COVID-19 has been illustrated. The role of IL-6 as a pleiotropic cytokine executing both pro and anti-inflammatory activities has been reviewed. ADAM 10, a metalloproteinase switches the anti-inflammatory pathway of IL-6 to pro inflammatory hence blocking the action of ADAM 10 could be a new therapeutic strategy to mitigate the proinflammatory action of IL-6. Furthermore, we explore the role of anti-IL6 agents, IL-6 receptor antibodies which were being used for autoimmune diseases but now are being repurposed for the therapy of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.